Board of Directors

board of directors
Eamonn Hobbs

Eamonn Hobbs

Chairman & Chief Executive Officer

Mr. Hobbs is an entrepreneurial senior executive with over 35 years of demonstrated success in profitable medical device and combination drug/device product business creation and growth, general management, sales and marketing, and product development.

He currently serves as a Visiting Scholar and Entrepreneur in Residence for the Translational Accelerator at Brigham and Women’s Hospital, Harvard Medical School. From July 2014 to January 2016, Mr. Hobbs served as the President and Chief Executive Officer of Antares Pharma, Inc., a specialty pharmaceutical and drug/device combination company focused on self-injection pharmaceutical products and technologies. From 2009 to 2013, he served as President and Chief Executive Officer of Delcath Systems, Inc., a specialty pharmaceutical and medical device public company specializing in cancer treatment.

Prior to Delcath, Mr. Hobbs served as President and Chief Executive Officer of AngioDynamics, Inc., a company he co-founded in 1988 as a division of E-Z-EM, Inc. which grew into a leading medical technology company and took public in 2004. Prior to starting AngioDynamics, Mr. Hobbs was Director of Marketing and Product Development at NAMIC; founder, President and Chief Executive Officer of Hobbs Medical, Inc.; and a Product Development Engineer at Cook Incorporated.

He also has served on numerous public and private company boards throughout his career. Mr. Hobbs received a B.S. degree in Plastics Engineering with a Biomaterials emphasis at the University of Massachusetts (Lowell).

Douglas Watson

Douglas Watson

Lead Independent Director

Mr. Watson is the former President and Chief Executive Officer of Novartis Corporation, the US subsidiary of Novartis AG. Mr. Watson’s career spanned 34 years with Geigy/Ciba-Geigy/Novartis, during which time he held a variety of positions in the UK, Switzerland and the US.

Mr. Watson joined Geigy (UK) Ltd in 1966, working first in Operations Research and then in Corporate Planning.  From 1986, he was President of Ciba US Pharmaceuticals Division until 1996, when he was appointed President & CEO of Ciba-Geigy Corporation. During this ten year period, Mr. Watson was an active member of the Pharmaceutical Research & Manufacturers Association (PhRMA) board in Washington, DC.

Mr. Watson became President & CEO of Novartis Corporation in 1997, when Ciba-Geigy & Sandoz merged. He elected to take early retirement from Novartis in May, 1999.

Mr. Watson currently serves as board member of BZL Inc., and a member of the advisory board of Cancer Expert Now Inc. Mr. Watson recently retired as Chairman of the board of OraSure Technologies Inc.

Prior board memberships include Novartis, Dendreon, Engelhard, Summit Bank, Wright Medical Group, BioMimetic Therapeutics, Delcath Systems, Javelin Pharmaceuticals, Genta, and Bionor Immuno AS.

Gary Onik, M.D.

Gary Onik, M.D.

Director

Gary M. Onik, MD, while still in radiology residency training in 1982, at the University of California – San Francisco, described a brand new cancer treatment concept – a radiological procedure based on the possibility of image guided thermal tumor ablation (destruction). His new procedure demonstrated a brand new approach and novel techniques for destroying a tumor through freezing or heating and then leaving it in place to be removed by the body rather than by surgery.

This was the very first demonstration of its kind and with it Dr. Onik literally created an entirely new field of medicine around the concept of minimally invasive cancer tumor destruction and removal by normal bodily processes, rather than through surgical removal.

In 1982, using cryosurgical ablation under ultrasound guidance, he developed the first new potentially curative treatment for unresectable liver cancer patients. This work spawned the development of image-guided radio-frequency (RF) ablation of liver tumors, and subsequently the field of what is now a 4th branch of cancer treatment, called “Interventional Oncology”.

At the same time as his work on hepatic cancer ablation, Dr Onik. developed the instrumentation and techniques that allowed for the cryosurgical ablation of prostate cancer, which is now an accepted alternative to radiation and radical prostatectomy and the preferred treatment for patients with radiation-recurrent prostate cancer . His concept of “focal therapy” for prostate cancer, treating only the prostate tumor rather than the whole gland, similar to a breast lumpectomy, is now a major research and treatment initiative in all of the major prostate cancer centers in the world.

The 3D Prostate Mapping Biopsy, which he has pioneered, maps the exact location of the cancer in the prostate gland allowing safer and more efficacious treatment. (See video).

His most recent development of “Irreversible Electroporation” (IRE), embodied in the “NanoKnife”, is the first of its kind “non-thermal” tumor ablation modality, which is now being used to successfully treat inoperable pancreatic carcinoma. One recently published study indicated it can double overall survival time. This modality also promises effective treatment for other inoperable tumors including those of the head and neck and the brain.

After years of development and refinement leading to approval of the device, Dr. Onik is the physician with the most experience in the world using the NanoKnife, and is able to bring that experience along with the great breadth of his practice in tumor ablation to the treatment of recurrent prostate cancer.

The concepts and techniques he developed have had a major impact on the treatment of cancer patients throughout the world and his work has been recognized by awards given to him by major societies in both medicine and engineering.

In addition to his medical practice, Dr. Onik is an Adjunct Professor of Mechanical Engineering at Carnegie Mellon University, working closely with his colleagues to develop the next generation of cancer fighting technologies.

His latest work, using immunotherapy to treat metastatic cancer, offers hope those patients with literally no other options.